

11/16/99
jc503 U.S. PTO

Attorney Docket No.: 5709.200-U.S.

PATENT

A
Seq. listing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL021372095US
Date of Deposit November 16, 1999

jc503 U.S. PTO
09/441313
11/16/99

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of

Applicant(s): Svendsen et al.

Title: α -amylase variants

46 pages of specification 4 sheets of drawings

4 sheets of Declaration and Power of Attorney

1 page of abstract 24 pages of sequence listing

[x] The filing fee is calculated as follows:

Basic Fee: \$760.00

Total Claims: $23 - 20 = 3 \times 18 =$ \$ 54.00

Independent Claims: $3 - 3 = 0 \times 78 =$ \$ 0

Total Fee: \$814.00


The benefit of application no. 09/193,068 filed on November 16, 1998 in the U.S.
is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$814, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 16, 1999



Elias J. Lambins, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

11/16/99 11:11 AM

Attorney Docket No.: 5709.200-U.S.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
Title: α -amylase variants
Applicants: Svendsen et al.

Sir:

Express Mail Label No. EL021372095US

Date of Deposit : November 16, 1999

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Carol A. McFarlane

(Name of person mailing paper(s) or fee)

Carol McFarlane

(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123